Sun Pharma is expected to show steady but moderate growth in its September second quarter (Q2 FY26) earnings, with analysts highlighting a combination of factors: a high base effect from last year’s Revlimid sales, weak performance at Taro and early-stage spending on the US launch of Leqselvi, the recently approved specialty drug.According to average broker […]
